Description: AFT Pharmaceuticals Limited is a pharmaceutical distributor and developer of pharmaceutical intellectual property. The Company's segments include New Zealand, Australia, Asia and Rest of World. The Company's products include Crystaderm, Maxigesic, Coco-scalp, Maxiclear, RestoraNail and Myconail, among others. The Company's NasoSURF Nebuliser is in pilot scale production. The Company is focused on conducting clinical for Maxigesic oral dose forms. The Company is also conducting clinical trials of Maxigesic intravenous (IV). Maxigesic PE is a cold and flu variant. Its subsidiary, AFT Pharmaceuticals (AU) Pty Ltd, is engaged in distribution of pharmaceuticals in Australia. Its subsidiary, AFT Pharmaceuticals Singapore Pte Ltd, is engaged in the registration of pharmaceuticals in Singapore. Its subsidiary, AFT Pharmaceuticals (S.E. Asia) Sdn Bhd, is engaged in the distribution of pharmaceuticals in Malaysia.
Home Page: www.aftpharm.com
AFP Technical Analysis
AmericaFirst Quantitative Funds
,
Phone:
877-217-8363
Officers
| Name | Title |
|---|---|
| Dr. Hartley Atkinson Ph.D. | Co-Founder, CEO, MD & Exec. Director |
| Ms. Marree Atkinson | Co-Founder, Chief of Staff & Exec. Director |
| Mr. Malcolm Tubby B.A., BA(Hon's), ICAEW, ICANZ | CFO & Company Sec. |
| Mr. Murray Keith | Group Marketing Mang. |
| Ms. Ioana Stanescu | Head of Drug Devel. |
| Mr. Calvin Mackenzie | Gen. Mang. of AFT Australia |
| Mr. Scott Crawford | Gen. Mang. of Promoted Products Australasia & South East Asia |
| Ms. Louise Clayton | Director of International Bus. |
Exchange: AU
Country: AU : Australia
Currency: Australian Dollar (A$)
| Forward PE: | 17.0648 |
|---|---|
| Trailing PE: | 22.3 |
| Price-to-Book MRQ: | 6.6525 |
| Price-to-Sales TTM: | 2.5368 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 97 |